非高密度脂蛋白胆固醇与载脂蛋白B在降脂治疗中应用的研究进展  

Research Progress in the Application of Non-high-density Lipoprotein Cholesterol and Apolipoprotein B in Lipid-lowering Therapy

作　　者：石睿[1] 李开炜 谭诚 干伟[2] 祝烨[1] SHI Rui;LI Kaiwei;TAN Cheng;GAN Wei;ZHU Ye(Department of Cardiology,West China Hospital,Sichuan University,Chengdu 610041;Department of Laboratory Medicine,West China Hospital,Sichuan University,Chengdu 610041,China)

机构地区：[1]四川大学华西医院心脏内科,成都市610041 [2]四川大学华西医院实验医学科,成都市610041

出　　处：《中国分子心脏病学杂志》2022年第5期4878-4882,共5页Molecular Cardiology of China

摘　　要：冠心病作为全球范围内死亡的主要病因之一,其传统的风险评估方法主要是检测低密度脂蛋白胆固醇(LDL-C)水平。LDL-C作为经典的降脂治疗的靶点,多年来已经得到了广泛的临床应用,并获得了很好的临床预测评估效果。然而LDL-C目前仍存在计算方法不准确、包含指标不完整、无法精确预测冠心病发生风险等问题。近年来,多项临床试验研究了非高密度脂蛋白胆固醇(Non-HDL-C)及载脂蛋白B(ApoB)对于冠心病患者预后的预测价值。特别是在某些特定患者中,NonHDL-C和ApoB被认为是较LDL-C能更准确地衡量心血管事件风险的指标,其检测也更加稳定、方便,因此可以作为临床降脂的新靶点。本文对Non-HDL-C与ApoB在降脂治疗中应用的研究进展进行综述。Coronary heart disease is one of the leading causes of death worldwide,and its risk assessment is mainly based on traditional low-density lipoprotein cholesterol(LDL-C)levels.LDL-C has been widely used in clinical practice as the target of classic lipid-lowering therapy for many years,which has shown a good clinical prediction and evaluation effect.However,LDL-C still has some deficiencies,such as inaccurate calculation methods,lack of some indicators,and inability to accurately predict the risk for coronary heart disease.Therefore,a number of clinical trials in recent years have investigated the prognostic value of non-highdensity lipoprotein cholesterol(Non-HDL-C)and apolipoprotein B(ApoB).In comparison with LDL-C,Non-HDL-C and ApoB are considered to be more accurate indicators of cardiovascular event risk,and their detection is more stable and convenient,so they can be used as promising targets for lipid-lowering treatment.This article aims to review the value of non-HDL-C and ApoB in lipidlowering therapy.

关 键 词：非高密度脂蛋白胆固醇 载脂蛋白B 低密度脂蛋白胆固醇 降脂治疗 冠心病 动脉粥样硬化性心血管疾病 

分 类 号：R541.4[医药卫生—心血管疾病]